葵花药业核心管理层调整

Group 1 - The former president of the company, Guan Yi, has resigned from the position of general manager due to personal reasons but will continue to serve as a director and hold relevant positions in the company's subsidiaries [2] - The company has experienced significant growth in revenue and net profit from 2021 to 2023, achieving double-digit year-on-year growth for three consecutive years [2] - However, the company has projected a net loss of approximately 240 million to 380 million yuan for the fiscal year 2025, representing a decline of 177.23% to 148.78% compared to the previous year [2] Group 2 - The company plans to enhance its management team by appointing experienced and influential professionals to operate in specialized lines [3] - There will be a continued investment in the health sector, leveraging the "Little Sunflower" brand to establish an "online-first + all-channel coverage" operational system [3] - The new management team members possess extensive industry experience and are well-aligned with the company's culture and operational model, which is expected to facilitate the implementation of the company's strategy and promote healthy and stable development [3]